Hepatocellular carcinoma
Conditions
Interventions
A:Hepatic Arterial Infusion of Oxaliplatin plus Raltitrexed
B:Oral sorafenib
Sponsors
Fujian Cancer Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. For the patients with primary liver cancer, the diagnosis standard is the standard set in the national health and Health Commission's "primary liver cancer diagnosis and treatment standard (2019 version)"; the BCLC stage standard is used for the stage; 2. The patients included shall be: (1) BCLC stage C patients who are not suitable for conventional TACE; (2) In BCLC stage B patients with multiple intrahepatic lesions or significant arteriovenous fistulas, conventional chemoembolization was ineffective; 3. Patients who have received local treatment before, such as surgery, TACE, RFA, radiotherapy, can be included in the study, and the pre-treatment should be stopped for more than 4 weeks; 4. Patients between 18-70 years old; 5. Bone marrow function (HB >=10 g/dl, WBC >=3000/uL, platelet count >=75000/uL), liver function (bilirubin <=3 mg / dl, transaminase <=200 U/L), kidney function (myoliver <=390 umol/L). Coagulation function was normal; 6. Patients with ECoG score of 0-2; 7. Patients willing to sign informed consent; 8. Patients willing to cooperate with regular follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients with decompensated liver function (including uncontrolled ascites, hepatic encephalopathy, acute or recent gastrointestinal bleeding within 2 weeks); 2. Patients with active infection; 3. Pregnant or lactating women; 4. Patients with serious complications, such as uncontrolled hypertension, coronary heart disease, diabetes, heart failure, etc; 5. Patients with expected survival less than 3 months; 6. Patients with extrahepatic metastasis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor response;overall survival; | — |
Countries
China
Contacts
Public ContactWenchang Yu
Fujian Cancer Hospital
Outcome results
None listed